Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 9

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Hepatol. Mar 28, 2017; 9(9): 469-476
Published online Mar 28, 2017. doi: 10.4254/wjh.v9.i9.469

Full Size Figure Download Figure

Figure 2 Box-plot diagram shows the alpha-fetoprotein level in the three groups. AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma.

Citation: Shaker MK, Abdel Fattah HI, Sabbour GS, Montasser IF, Abdelhakam SM, El Hadidy E, Yousry R, El Dorry AK. Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients. World J Hepatol 2017; 9(9): 469-476
URL: https://www.wjgnet.com/1948-5182/full/v9/i9/469.htm
DOI: https://dx.doi.org/10.4254/wjh.v9.i9.469

Shaker MK, Abdel Fattah HI, Sabbour GS, Montasser IF, Abdelhakam SM, El Hadidy E, Yousry R, El Dorry AK. Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients. World J Hepatol 2017; 9(9): 469-476 [PMID: 28396717 DOI: 10.4254/wjh.v9.i9.469]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.